Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2004;328:524-525 (28 February), doi:10.1136/bmj.328.7438.524-b
| The first 150 words of the full text of this article appear below. |
EDITORWe report our preliminary findings on prescribing of antidepressants in general practice, in response to the recommendation by the regulatory agency for medicines and healthcare products to withdraw selective serotonin reuptake inhibitors from use in paediatric depression.1 2
We used the general practice research database to analyse use between 1 January 1992 and 31 December 2001 (88 522 prescriptions issued to 23 999 children and adolescents).3 Fifty nine per cent of antidepressant prescriptions were for tricyclics; 39% were for selective serotonin reuptake inhibitors. The most commonly prescribed antidepressants were imipramine (25% of prescriptions), fluoxetine (19%), and amitriptyline (18%). Paroxetine, sertraline, citalopram, venlafaxine, and fluvoxamine accounted for 21% of prescriptions. Sixty three per cent, 35%, and 2% of patients were given tricyclics, selective serotonin reuptake inhibitors, and other antidepressants, respectively, as the first antidepressant prescribed.
|
|
Credit: ALEX JAMES PHOTOGRAPHIC/PHOTONICA
|
In patients aged 10 years or younger the most commonly recorded
Macey L Murray, research fellow
macey.murray@ulsop.ac.uk, Centre for Paediatric Pharmacy Research, School of Pharmacy, University of London, London WC1N 1AX
Ian C K Wong, director
Centre for Paediatric Pharmacy Research, School of Pharmacy, University of London, London WC1N 1AX
Corinne S de Vries, senior lecturer
Department of Pharmacoepidemiology, Postgraduate Medical School, University of Surrey, Guildford GU2 7DJ